670P Phase I Trial of the Delta-Like Ligand-3 (DLL3)/CD3 IgG-Like T Cell Engager BI 764532 in Patients (pts) with DLL3-positive Tumors: Updated Data
Annals of Oncology(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined